Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19327711 | METHODS OF IMPROVING LUNG FUNCTION | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19327682 | METHODS OF IMPROVING LUNG FUNCTION | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19278338 | TOPICAL COMPOSITIONS | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19070439 | METHODS OF IMPROVING LUNG FUNCTION | March 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18990585 | USE OF MARIBAVIR IN TREATMENT REGIMENS | December 2024 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18990486 | USE OF MARIBAVIR IN TREATMENT REGIMENS | December 2024 | July 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18910861 | HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATER | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18910839 | HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATER | October 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18806346 | SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18679403 | DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATITIS | May 2024 | August 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18660547 | PREPARATION METHOD FOR POLYSACCHARIDE SPHERICAL GEL RESIN | May 2024 | April 2025 | Allow | 11 | 2 | 0 | No | No |
| 18602528 | ANTIOXIDANT COMPOSITION COMPRISING POLYDATIN AND ACETYLCYSTEINE | March 2024 | July 2025 | Allow | 16 | 0 | 0 | No | No |
| 18602065 | Self-immolative plasmid backbone | March 2024 | October 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18600413 | VIRAL RECEPTOR BOUND WITH SIALIC ACID COMPOUNDS | March 2024 | February 2026 | Abandon | 23 | 1 | 0 | No | No |
| 18442374 | METHOD FOR DIGESTING NUCLEIC ACID IN A SAMPLE | February 2024 | October 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18437875 | METHOD OF STABILIZING MOLECULES WITHOUT REFRIGERATION USING WATER SOLUBLE POLYMERS AND APPLICATIONS THEREOF IN PERFORMING CHEMICAL REACTIONS | February 2024 | December 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18428348 | NOVEL CROSSLINKED ALGINIC ACID | January 2024 | January 2026 | Allow | 24 | 1 | 1 | Yes | No |
| 18423959 | METHODS FOR ISOLATING DNA FROM A BLOOD SAMPLE | January 2024 | August 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18422779 | LOW GLYCEMIC SUGAR COMPOSITION | January 2024 | November 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18411746 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF INFECTIONS AND ANTIBACTERIAL-INDUCED DYSFUNCTIONS | January 2024 | March 2026 | Allow | 26 | 1 | 1 | Yes | No |
| 18545981 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | December 2023 | October 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18530920 | METHODS AND COMPOSITIONS FOR THERAPEUTIC SKIN TREATMENTS IN DERMATOLOGICAL PROCEDURES AFFECTING SKIN'S BARRIER | December 2023 | June 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18567332 | BIOMASS PRODUCTION | December 2023 | September 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18513436 | DISSOLVABLE NASAL SINUS SPONGE | November 2023 | May 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18510165 | ANIMAL TREATMENTS | November 2023 | March 2026 | Allow | 28 | 1 | 1 | Yes | No |
| 18506169 | METHODS FOR TREATING AND PHARMACEUTICAL COMPOSITIONS | November 2023 | June 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18487690 | MODULATORS OF ALPHA-1 ANTITRYPSIN | October 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18378011 | CELL-BASED ASSAY FOR QUANTIFYING THE POTENCY AND EFFICACY OF CANNABINOIDS AND/OR TERPENOIDS, AND METHODS OF USE THEREOF | October 2023 | April 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18470273 | BETA GLUCAN IMMUNOPHARMACODYNAMICS | September 2023 | December 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18465722 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | September 2023 | April 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18243169 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | September 2023 | January 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18456839 | COMPOSITIONS FOR THE TREATMENT OF DRY EYE | August 2023 | April 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18232135 | Use of Polysaccharide for Treating ST-Elevation Myocardial Infarction and Diseases of the Digestion System | August 2023 | December 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18226034 | METHODS OF DETECTING TUMOR PROGRESSION VIA ANALYSIS OF CELL-FREE NUCLEIC ACIDS | July 2023 | September 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18221036 | METHODS AND MATERIALS FOR ASSESSING AND TREATING OBESITY | July 2023 | July 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18220779 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | July 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18217025 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | June 2023 | March 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18327621 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | June 2023 | March 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18202565 | METHOD FOR PRODUCING ALLULOSE CRYSTALS | May 2023 | December 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 18251959 | COMPOSITION FOR CARING FOR KERATIN MATERIALS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18137740 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | April 2023 | November 2025 | Allow | 31 | 2 | 1 | Yes | Yes |
| 18296796 | COMPOSITION FOR IMPROVING, PREVENTING OR TREATING MUSCULAR DISORDERS INCLUDING SULFONAMIDE-BASED COMPOUNDS | April 2023 | March 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18018615 | DEVICE AND METHOD FOR PREPARING SUCROSE-6-ESTER | January 2023 | February 2026 | Allow | 37 | 1 | 0 | No | No |
| 18006776 | Human Milk Oligosaccharide for Improving Health of Intestinal Microenvironment and Use Thereof | January 2023 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18076607 | METHOD FOR PRODUCING ALLULOSE CRYSTALS | December 2022 | December 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 18075640 | ORAL DELIVERY OF HEPARINS | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18000034 | COMPOSITION FOR INHIBITING HAIR GRAYING, AND USE THEREOF | November 2022 | December 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17926772 | AMPHIPHILIC CARBOHYDRATE COMPOUNDS | November 2022 | December 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17998902 | ARABINOSE AND PREPARATION AND USE THEREOF | November 2022 | February 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 17923465 | METHOD OF MAKING AND USING A SKIN MOISTURIZING FORMULATION | November 2022 | January 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 17981348 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | November 2022 | September 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17977654 | KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID | October 2022 | March 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17922075 | HELP APHERESIS FOR THE TREATMENT OF SERIOUSLY ILL COVID-19 PATIENTS | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17921065 | Ophthalmic Composition | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17919360 | DIAGNOSIS AND TREATMENT OF COVID-19 | October 2022 | March 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17996058 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | October 2022 | October 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17914974 | NUCLEIC ACIDS EXTRACTION SYSTEM AND METHOD BASED ON 3D-PRINTED MICRODEVICE | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17940080 | LIQUID AND AGAR FLUOROPHORE PHANTOM | September 2022 | December 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17909051 | ANTIBACTERIAL AND ANTIFUNGAL POLYKETIDES FROM ENVIRONMENTAL AMYCOLATOPSIS SPP | September 2022 | March 2026 | Allow | 42 | 1 | 1 | Yes | No |
| 17908391 | INTESTINAL TRACT FUNCTION-IMPROVING AGENT | August 2022 | February 2026 | Abandon | 42 | 1 | 1 | No | No |
| 17905381 | PASTE-TYPE COSMETIC CONTAINING NATURAL MOISTURIZING FACTOR | August 2022 | November 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17802711 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF LUNG INJURY | August 2022 | December 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17905089 | COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF LUNG DISEASES AND CONDITIONS | August 2022 | November 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17801642 | SYNTHESIS OF GLYCOSYLATED SPHINGOID BASES OF INTEREST OR ANALOGUES THEREOF | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17885464 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | August 2022 | December 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17798173 | Cyclodextrins as dental cleaning powders | August 2022 | August 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17795983 | NISIN-PERMEABILIZED MICROBIAL CELL CATALYSTS | July 2022 | November 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17795666 | TREATMENT FOR CHONDRODYSTROPHIA | July 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17873451 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | July 2022 | April 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17792099 | COMBINATION AND METHOD FOR TREATING SUBJECT USING ALGINATE | July 2022 | August 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17851684 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | June 2022 | January 2026 | Allow | 43 | 4 | 1 | Yes | No |
| 17788422 | DENDROBIUM OFFICINALE OLIGOSACCHARIDE, DENDROBIUM OFFICINALE OLIGOSACCHARIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | June 2022 | January 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17788399 | PREPARATION OF REGENERATED POLYSACCHARIDES | June 2022 | August 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17842115 | NOVEL CROSSLINKED ALGINIC ACID | June 2022 | January 2026 | Allow | 43 | 1 | 1 | Yes | No |
| 17785478 | ENRICHMENT METHOD | June 2022 | January 2026 | Allow | 43 | 1 | 1 | Yes | No |
| 17837598 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | June 2022 | November 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17779252 | PROCESS FOR PRODUCING A COMPOSITION COMPRISING A CROSSLINKED HYDROGEL | May 2022 | February 2026 | Allow | 45 | 2 | 1 | Yes | No |
| 17777152 | Synthesis of human milk oligosaccharides by a Beta-N-acetylhexosaminidase from Haloferula sp. | May 2022 | November 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17776356 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17436807 | METHOD FOR PRODUCTION OF FUNCTIONAL POLYSACCHARIDE AND COSMETIC COMPOSITION | April 2022 | September 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17769875 | COMBINATION PREPARATIONS OF 3-N-FORMYLHYDROXYLAMINOPROPYL PHOSPHONIC ACID DERIVATIVES OR 3-N-ACETYLHYDROXYLAMINOPROPYL PHOSPHONIC ACID DERIVATIVES WITH CLINDAMYCIN AND ARTESUNATE | April 2022 | September 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17764606 | Bio-based polysaccharide foil | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17764874 | NUCLEOTIDE PROBES | March 2022 | December 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17654700 | OLIGONUCLEOTIDE MANUFACTURING METHOD | March 2022 | November 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17753655 | MODIFIED STARCHES FOR HOME CARE AND PERSONAL CARE | March 2022 | July 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17637906 | Edible Formulations Based on Active Ingredients and Arginine | February 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17633408 | Novel Nucleic Acid Purification Chemistry | February 2022 | August 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17630133 | COMPOSITIONS AND METHODS FOR UPREGULATION OF HUMAN FETAL HEMOGLOBIN | January 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17629466 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | January 2022 | June 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17576161 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS FOOD INGREDIENTS AND METHODS OF PRODUCING THEREOF | January 2022 | March 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17564460 | COMPOSITION FOR INHIBITING IMMUNE CELL PROLIFERATION COMPRISING SIALYLLACTOSE OR DERIVATIVE THEREOF AND METHOD THEREOF | December 2021 | January 2026 | Abandon | 49 | 2 | 0 | No | No |
| 17617080 | OLIGONUCLEOTIDE CONTAINING BLOCKER | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17599472 | TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINT | September 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17438186 | TREATMENT OF ONCOGENE-DRIVEN CANCERS | September 2021 | July 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17432821 | SYNTHESIS OF BIOMIMETIC CELL WALL STRUCTURE | August 2021 | August 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17361164 | Targeted Delivery of Therapeutic Molecules | June 2021 | November 2025 | Abandon | 53 | 1 | 2 | No | No |
| 17353613 | PRODUCTION OF BIOACTIVE OLIGOSACCHARIDES | June 2021 | May 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17326068 | PROCESS FOR THE ISOLATION OF NOVEL GLYCOSIDES FROM PTEROCARPUS MARSUPIUM AND THEIR THERAPEUTIC EFFECTS | May 2021 | May 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17269981 | GEMCITABINE PRODRUGS | February 2021 | August 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17048451 | HIGH MOLECULAR WEIGHT HYALURONIC ACID FOR TREATMENT AND PREVENTION OF SEVERE OCULAR SURFACE DISEASE | October 2020 | January 2025 | Allow | 51 | 5 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner SHIAO, YIH-HORNG works in Art Unit 1691 and has examined 25 patent applications in our dataset. With an allowance rate of 68.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 41 months.
Examiner SHIAO, YIH-HORNG's allowance rate of 68.0% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SHIAO, YIH-HORNG receive 1.80 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SHIAO, YIH-HORNG is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +72.7% benefit to allowance rate for applications examined by SHIAO, YIH-HORNG. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 72% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.